Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
Adicet Bio (Nasdaq: ACET) announced its upcoming oral presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference. The event is scheduled for October 16-17, 2024, in Philadelphia, PA.
The presentation, titled 'ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications', will be delivered by Shon Green, Ph.D. It is part of the 'Novel Targets and Effector Cells' session and is assigned Abstract Number 8.
The presentation is scheduled for October 17, 2024, from 11:15 a.m. to 11:30 a.m. ET. Adicet Bio, a clinical stage biotechnology company, focuses on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Adicet Bio (Nasdaq: ACET) ha annunciato la sua prossima presentazione orale alla conferenza 2024 Advancing Gene and Cell Therapies for Cancer della American Society of Gene & Cell Therapy (ASGCT). L'evento è programmato per 16-17 ottobre 2024, a Filadelfia, PA.
La presentazione, intitolata 'ADI-270: una terapia CAR γδ T cell armata allogenica anti-CD70 progettata per una maggiore potenza e persistenza contro più indicazioni oncologiche', sarà tenuta da Shon Green, Ph.D.. Essa fa parte della sessione 'Nuovi target e cellule effettrici' ed è assegnata il Numero di Abstract 8.
La presentazione è programmata per 17 ottobre 2024, dalle 11:15 alle 11:30 ET. Adicet Bio, un'azienda biotecnologica in fase clinica, si concentra sulla scoperta e lo sviluppo di terapie allogeniche con cellule T gamma delta per malattie autoimmuni e cancro.
Adicet Bio (Nasdaq: ACET) anunció su próxima presentación oral en la conferencia 2024 Advancing Gene and Cell Therapies for Cancer de la American Society of Gene & Cell Therapy (ASGCT). El evento está programado para 16-17 de octubre de 2024, en Filadelfia, PA.
La presentación, titulada 'ADI-270: una terapia CAR γδ T cell alogénica armada anti-CD70 diseñada para una mayor potencia y persistencia contra múltiples indicaciones oncológicas', será entregada por Shon Green, Ph.D.. Forma parte de la sesión 'Nuevos objetivos y células efectoras' y se le asigna el Número de Resumen 8.
La presentación está programada para 17 de octubre de 2024, de 11:15 a.m. a 11:30 a.m. ET. Adicet Bio, una empresa de biotecnología en etapa clínica, se enfoca en descubrir y desarrollar terapias con células T gamma delta alogénicas para enfermedades autoinmunes y cáncer.
Adicet Bio (Nasdaq: ACET)는 미국 유전자 및 세포 치료 학회의 2024 Advancing Gene and Cell Therapies for Cancer 회의에서의 구두 발표를 발표했습니다. 이 행사는 2024년 10월 16-17일, 필라델피아, PA에서 열릴 예정입니다.
발표 제목은 'ADI-270: 다수의 종양학적 적응증에 대한 향상된 효능 및 지속성을 위해 설계된 알로겐 항-CD70 CAR γδ T 세포 요법'이며, Shon Green 박사가 발표할 예정입니다. 이는 '새로운 표적 및 효과 세포' 세션의 일부로, 초록 번호 8로 지정되어 있습니다.
발표는 2024년 10월 17일, 오전 11시 15분부터 11시 30분까지 ET에 예정되어 있습니다. Adicet Bio는 임상 단계의 생명공학 회사로, 자가 면역 질환 및 암에 대한 알로겐 γδ T 세포 요법을 발견하고 개발하는 데 중점을 두고 있습니다.
Adicet Bio (Nasdaq: ACET) a annoncé sa prochaine présentation orale lors de la conférence 2024 Advancing Gene and Cell Therapies for Cancer de la Société Américaine de Thérapie Génétique et Cellulaire (ASGCT). L'événement est prévu pour le 16-17 octobre 2024, à Philadelphie, PA.
La présentation, intitulée 'ADI-270 : une thérapie CAR γδ T cell allogénique blindée anti-CD70 conçue pour une puissance et une persistance accrues contre de multiples indications oncologiques', sera délivrée par Shon Green, Ph.D.. Elle fait partie de la session 'Cibles Nouvelles et Cellules Effectrices' et est assignée le Numéro de Résumé 8.
La présentation est prévue pour le 17 octobre 2024, de 11h15 à 11h30 ET. Adicet Bio, une entreprise de biotechnologie au stade clinique, se concentre sur la découverte et le développement de thérapies T-cell gamma delta allogéniques pour les maladies auto-immunes et le cancer.
Adicet Bio (Nasdaq: ACET) hat seine bevorstehende mündliche Präsentation auf der 2024 Advancing Gene and Cell Therapies for Cancer Konferenz der American Society of Gene & Cell Therapy (ASGCT) angekündigt. Die Veranstaltung findet am 16.-17. Oktober 2024 in Philadelphia, PA, statt.
Die Präsentation mit dem Titel 'ADI-270: Eine gepanzerte allogene Anti-CD70 CAR γδ T-Zell-Therapie, die für eine verbesserte Potenz und Persistenz gegen multiple Onkologie-Indikationen entwickelt wurde' wird von Shon Green, Ph.D. gehalten. Sie ist Teil der Sitzung 'Neue Ziele und Effektorenzellen' und trägt die Abstract-Nummer 8.
Die Präsentation ist für 17. Oktober 2024, von 11:15 Uhr bis 11:30 Uhr ET angesetzt. Adicet Bio, ein Biotechnologieunternehmen in klinischer Phase, konzentriert sich auf die Entdeckung und Entwicklung allogener gamma delta T-Zell-Therapien für Autoimmunerkrankungen und Krebs.
- None.
- None.
Details of the oral presentation are as follows:
Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications
Session Name: Novel Targets and Effector Cells
Abstract Number: 8
Presenting Author: Shon Green, Ph.D.
Date and Time: October 17, 2024; 11:15 a.m. – 11:30 a.m. ET
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930541778/en/
Adicet Bio, Inc.
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
What conference will Adicet Bio present at in October 2024?
What is the title of Adicet Bio's presentation at the ASGCT 2024 conference?
Who will be presenting Adicet Bio's research at the ASGCT 2024 conference?
When is Adicet Bio's (ACET) presentation scheduled at the ASGCT 2024 conference?
What type of therapies does Adicet Bio (ACET) focus on developing?
